IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES IDIQ CONTRACT. POP 9/27/21-9/26/26. NTE $3.5 MILLION. FIRST TASK ORDER 01 OBLIGATED IN THE AMOUNT O

体外代谢和非临床 ADME 研究 IDIQ 合同。

• 批准号: 10505766
• 负责人: MARY BASTIDA
• 金额: $ 8.97万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-27 至 2026-09-26
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10505766
• 关键词: ADME Study; Contracts; Data; In Vitro; Investigational Drugs; Metabolism; National Institute of Drug Abuse; Permeability; Pharmaceutical Preparations; Program Development; Research Personnel; United States Food and Drug Administration; in vivo; novel therapeutics

The objective of this contract is to carry out in vitro metabolism and permeability and in vivo ADME studies to support the medications development program of the National Institute on Drug Abuse (NIDA). NIDA and NIDA sponsored investigators will use the data obtained for submissions to the Food and Drug Administration (FDA) in support of Investigational New Drugs (INDs) and New Drug Applications (NDAs).

该合同的目的是进行体外代谢和渗透性以及体内ADME研究，以支持国家药物滥用研究所（NIDA）的药物开发计划。NIDA和NIDA申办的研究者将使用获得的数据提交给美国食品药品监督管理局（FDA），以支持新药研究（IND）和新药申请（NDA）。